News

Press Release
Production of Dermal Injectors Delayed by China Work Stoppage Affecting Critical Component
Production of Dermal Injectors Delayed by China Work Stoppage Affecting Critical ComponentInitial run of commercial-grade...
Press Release
Commercial-Grade Replicel Injectors RepliCel in Production
Commercial-Grade Replicel Injectors RepliCel in ProductionInitial units will be dedicated to the functional and clinical testing needed...
Press Release
RepliCel Announces its Incoming Board of Directors
RepliCel Announces its Incoming Board of DirectorsSuccessful Annual General Meeting Confirms Director Slate for 2020VANCOUVER,...
Press Release
RepliCel Provides 2019 Year-End Update
RepliCel Provides 2019 Year-End UpdateNotable Milestones for the Company’s ProgramsVANCOUVER, BC, CANADA – 26 November 2019 – RepliCel...
Press Release
Clinical Data Published from RepliCel’s Skin Rejuvenation Study
Clinical Data Published from RepliCel’s Skin Rejuvenation StudyA paper entitled, “Autologous Cell Therapy for Aged Human...
Press Release
RepliCel Closes First Tranche of Private Placement Financing of Preferred Shares
RepliCel Closes First Tranche of Private Placement Financing of Preferred SharesNot for distribution to U.S....
Press Release
RepliCel's Partner, YOFOTO (China) Health, Unveils its Inaugural Cell Therapy Manufacturing Facility in China
RepliCel's Partner, YOFOTO (China) Health, Unveils its Inaugural Cell Therapy Manufacturing Facility in ChinaYOFOTO (China)...
Press Release
RepliCel Life Sciences Retains Dermatology Sales and Marketing Executive to Guide the Global Commercial Strategy for its Automated Dermal Injector
RepliCel Life Sciences Retains Dermatology Sales and Marketing Executive to Guide the Global Commercial Strategy...
Press Release
RepliCel Secures Several New Patents for its Regenerative Medicine Technologies
RepliCel Secures Several New Patents for its Regenerative Medicine TechnologiesTendon Regeneration, Skin Rejuvenation and Dermal Injector...
Press Release
RepliCel's Licensee Building Momentum in China with Facility and Team
RepliCel's Licensee Building Momentum in China with Facility and TeamYOFOTO (China) Health Announces Initiation of...
Press Release
RepliCel Reignites its First-in-Japan Strategy
RepliCel Reignites its First-in-Japan StrategyNext-stage trials in Japan present market launch opportunities for RepliCel’s skin...
Press Release
RepliCel CEO Provides 2019 Shareholder Update
With a new strategic plan, RepliCel prioritizes focus on commercial revenueVANCOUVER, BC, CANADA – 5 March, 2019 –...
Events
2018 GCFF Shenzhen Investing in North American Innovation Conference
RepliCel is presenting November 29, 2018 to Chinese attendees looking to invest in North American...
Events
Collaboration Meetings with YOFOTO & Participation in the YOFOTO 2018 Global Business Seminar
RepliCel and YOFOTO management will conduct their inaugural joint steering committee meetings on December 4-6,...
Events
2019 EBD Biotech Showcase
RepliCel is excited to have been chosen to present at next year's EBD Biotech Showcase...
Press Release
RepliCel Life Sciences Appoints Head of Clinical and Regulatory Affairs
Appointment of Dr. Goessens-Rueck strengthens management team and fulfils commitment to promote female leadership in...
Press Release
RepliCel Announces Federal Grant Funding for Collaboration with the University of Victoria, Canada
The National Sciences and Engineering Research Council of Canada has funded a University of Victoria...
Press Release
RepliCel Announces Federal Grant Funding for Collaboration with the University of Victoria, Canada (Copy)
The National Sciences and Engineering Research Council of Canada has funded a University of Victoria...
As Seen In
Groundbreaking Biotech Company Takes Major Step Forward with Deal with Chinese Partner
Canada-based biotech company signs major deal with Chinese partner to advance groundbreaking technology in the...
Press Release
RepliCel Life Sciences Appoints New Chief Financial Officer
VANCOUVER, Oct. 17, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2)...

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.